Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Hamartoma Syndrome, Multiple 1Glioblastoma 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Vorinostat 2nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Hydroxychloroquine 1Dasatinib 1DOXO-EMCH 1Cetuximab 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Malignant Solid Tumour × dactolisib × Clear all
NCT01343498 2015-05-01

Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
33 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡